M. Ruzanov

发表

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.

J. Fargnoli, S. Sheriff, A. Mathur, 2020, ACS medicinal chemistry letters.

Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.

J. Fargnoli, S. Sheriff, B. Fink, 2018, ACS medicinal chemistry letters.

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)

E. Pai, B. Neel, N. Chirgadze, 2014, BMC Structural Biology.

Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGF beta RI).

Amol G. Dikundwar, J. Fargnoli, S. Sheriff, 2018 .

Tricyclic Sulfones as Potent, Selective and Efficacious RORγt Inverse Agonists - Exploring C6 and C8 SAR Using Late-Stage Functionalization.

Michael G. Yang, D. Shuster, C. Weigelt, 2020, Bioorganic & medicinal chemistry letters.

Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists.

Michael A. Galella, D. Shuster, D. Shen, 2019, ACS medicinal chemistry letters.

Discovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization.

Alan S. Futran, Vijay T. Ahuja, Shana L. Posy, 2022, Journal of medicinal chemistry.

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

S. Spergel, K. McIntyre, D. Shuster, 2019, Journal of medicinal chemistry.

Signal transfer in human protein tyrosine phosphatase PTP1B from allosteric inhibitor P00058

E. Pai, B. Neel, N. Chirgadze, 2021, Journal of Biomolecular Structure and Dynamics.

Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.

Michael G. Yang, D. Shuster, C. Weigelt, 2021, ACS medicinal chemistry letters.

Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.

D. Shuster, J. Macor, C. Weigelt, 2020, ACS medicinal chemistry letters.

Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR.

Eric T Baldwin, Martin C. Wright, Andrew J Tebben, 2015, Journal of molecular biology.

Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.

S. E. Kiefer, J. Krupinski, Srinivas Cheruku, 2022, Journal of medicinal chemistry.

Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.

James Lin, K. McIntyre, D. Shuster, 2020, Journal of medicinal chemistry.

Substituted Diaryl Ether Compounds as Retinoic Acid-Related Orphan Receptor-γt (RORγt) Agonists.

Zhuyin Li, C. Weigelt, B. Fink, 2021, Bioorganic & medicinal chemistry letters.

Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (RORγt) agonists.

Zhuyin Li, C. Weigelt, B. Fink, 2020, Bioorganic & medicinal chemistry letters.

Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt ‒ Identification of a Potent, Selective Series with Biologic-Like In Vivo Efficacy.

K. McIntyre, D. Shuster, J. Macor, 2019, Journal of medicinal chemistry.

Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach.

D. Shuster, J. Macor, C. Weigelt, 2020, ACS medicinal chemistry letters.

Crystal structures of apo and inhibitor-bound TGFβR2 kinase domain: insights into TGFβR isoform selectivity.

D. Xie, S. Sheriff, Chunhong Yan, 2016, Acta crystallographica. Section D, Structural biology.

Crystal structure of the tyrosine phosphatase SHP-2 with E139D mutation

N. Chirgadze, G. Kisselman, W. Qiu, 2013 .

The Crucial Role of Conserved Intermolecular H-bonds Inaccessible to the Solvent in Formation and Stabilization of the TL5·5 SrRNA Complex*

V. Lim, B. Eliseev, O. Nikonov, 2005, Journal of Biological Chemistry.

Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1).

D. Xie, S. Sheriff, D. Lipovšek, 2020, Acta crystallographica. Section F, Structural biology communications.

Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI).

Amol G. Dikundwar, J. Fargnoli, S. Sheriff, 2018, Bioorganic & medicinal chemistry.

Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as ROR gamma t inverse agonists.

C. Weigelt, A. Mathur, Hai-yun Xiao, 2019 .

Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.

C. Weigelt, A. Mathur, Hai-yun Xiao, 2019, Bioorganic & medicinal chemistry letters.

Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313.

Michael G. Yang, D. Shuster, C. Weigelt, 2021, Journal of medicinal chemistry.

Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (RORγt) agonists.

C. Weigelt, B. Fink, T. Huynh, 2020, Bioorganic & medicinal chemistry letters.